Company: NCEL
Filing Date: 2025-02-10
Form Type: 425
Source: 0001213900-25-011502
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: 425
Chunk 2
---
Target Innovation for Diabetes

NLS is pioneering DOXA (Dual Orexin and Multi-Pathway
Modulation), a next-generation therapeutic approach integrating orexin receptor agonism, neuroprotective pathways, and metabolic
regulation to holistically manage diabetes and its systemic complications.

Unlike conventional approaches that primarily
target incretin signaling, DOXA leverages multi-target mechanisms to synchronize metabolic and neurological pathways by
acting on:

| ● | Orexin Signaling (OX1R/OX2R): Aiming to                                                                                            
 restore energy balance, cognitive function, and metabolic stability, counteracting diabetes-related fatigue and neurodegeneration. |

| ● | Sigma-1 Receptor (Sig-1R) Modulation: Aiming                                                                       
 to reduce oxidative stress, neuroinflammation, and insulin resistance, critical factors in diabetes complications. |

| ● | Cathepsin Inhibition (CTSS/CTSL): Aiming                                                   
 to protect neuronal integrity and β-cell survival, crucial for long-term metabolic health. |

| ● | Sodium-Glucose Cotransporter-2 (SGLT2) Modulation: Aiming                     
 to improve glucose metabolism while reducing neuropathic and vascular damage. |

| ● | Adiponectin Receptor Activation: Aiming                                                            
 to enhance insulin sensitivity and mitochondrial function, addressing core metabolic dysfunctions. |

Scientific Momentum: Breakthrough Findings to Be Presented at ASCP 2025

Preclinical studies to be presented at the 2025
ASCP Annual Meeting demonstrate that DOXA compounds:

| ● | Restore orexinergic function, improving metabolic 
 balance and sleep-wake disturbances.              |

| ● | Reduce inflammatory markers and neurodegeneration, 
 preventing diabetes-induced neuronal damage.       |

| ● | Enhance β-cell survival and glucose metabolism,                                               
 positioning DOXA as a disease-modifying therapy rather than a glucose-dependent intervention. |

Beyond its individual potential, DOXA is
expected to significantly outperform existing treatments when combined with Islet transplantation. By leveraging the ability of DOXA
to enhance metabolic regulation and insulin sensitivity, the DOXA-Islet therapy combination is positioned to set a new standard in
diabetes care.

Positioning NLS Pharmaceutics and Kadimastem as Leaders in Diabetes Innovation

The anticipated merger between NLS (Nasdaq:
NLSP) and Kadimastem (TASE: KDST) is intended to bring together two complementary platform technologies—Kadimastem’s
expertise in